We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.
We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.
Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland